Inhibitor Therapeutics Seeks Approval for 20M Share Incentive Plan Amid Going Concern

summarizeSummary

Inhibitor Therapeutics filed its definitive proxy for the September 15, 2026 annual meeting, seeking approval of a 20 million share incentive plan. The filing also references the company's going concern warning and a $3.0 million default judgment disclosed in its recent 10-Q.

check_boxKey Events · Corporate Governance and Compliance · INTI

• 20M Share Incentive Plan Proposed

  Shareholders will vote on the 2025 Share Incentive Plan, which authorizes up to 20 million shares (plus annual increases of 1% of outstanding shares starting 2027). If approved, this could significantly dilute existing holders.

• Going Concern Warning

  The company's recent 10-Q disclosed a going concern warning with only $515,758 in cash, indicating substantial doubt about its ability to continue operations.

• $3.0M Default Judgment

  The 10-Q also revealed a $3.0 million default judgment against an investor, adding a material legal liability to the company's financial challenges.

• Annual Meeting Set for Sept 15

  The virtual annual meeting will be held on September 15, 2026, where shareholders will vote on the incentive plan, director elections, auditor ratification, say-on-pay, and other proposals.

auto_awesomeAnalysis · INTI · Life Sciences

The proxy statement asks shareholders to approve a new equity incentive plan with a 20 million share reserve, which could significantly dilute existing holders if fully utilized. This comes as the company disclosed a going concern warning and a $3.0 million default judgment in its recent 10-Q, highlighting the need for equity-based compensation to retain talent while facing severe cash constraints.